Theodorus has contributed to a $23.8m series A round for NeuVasQ, the neurological disease drug developer spun out of Université libre de Bruxelles.

Belgium-based neurological disorder drug developer NeuVasQ Biotechnologies raised €20m ($23.8m) yesterday in a series A round featuring Theodorus, the university venture arm of Université libre de Bruxelles (ULB). Venture capital firm Newton Biocapital led the $11.9m private investment portion of the round, which included unnamed angel investors. Theodorus participated through its fourth fund, Theodorus IV.…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.